Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MAC-321 · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| MAC-321 | DRUG | - |
Inclusion Criteria: * Recurrence of non-small cell lung cancer after at least 1 prior chemotherapy regimen containing a platinum agent * Recovery from all acute side effects of prior therapies (with the exception of hair loss) * Adequate bone marrow, liver, and kidney function Exclusion Criteria: ...
MAC-321 is an investigational small molecule being studied in oncology for the treatment of carcinoma, non-small-cell lung cancer, and colorectal neoplasms. It has been evaluated in Phase 2 clinical trials for these indications.
MAC-321 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
MAC-321 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for any use.
MAC-321 has been studied in two completed Phase 2 trials: NCT00063219 in non-small cell lung cancer refractory to platinum-based therapy and NCT00063427 in colorectal cancer. Both trials are completed.
No alternative names for MAC-321 have been identified in the available information. It is referred to solely as MAC-321 in clinical trial records.